Aestas Pharma

Aestas Pharma is a private, pre-clinical stage biotech founded in 2016 and headquartered in Durham, North Carolina, with a presence in San Diego. The company is developing a dual-platform strategy targeting Alzheimer's disease, combining diagnostic imaging agents with therapeutic small molecules to facilitate early detection and disease-modifying treatment. Operating pre-revenue, Aestas is positioned in the high-need, high-value Alzheimer's market but faces significant scientific, clinical, and competitive risks inherent to the neurology space. Its success hinges on advancing its pipeline from pre-clinical research into human clinical trials.

Small molecule platform for integrated diagnostic imaging agents and disease-modifying therapeutics targeting Alzheimer's disease pathology.

The Alzheimer's competitive landscape is dominated by large pharma (Eli Lilly, Biogen, Roche) with approved or late-stage disease-modifying antibodies. The diagnostic space includes companies like GE Healthcare, Life Molecular Imaging, and Cerveau Technologies. Aestas is a very early-stage entrant competing in one of the most challenging and crowded therapeutic areas.